More recently, studies of ovarian carcinoma suggested that tau may be a marker for paclitaxel sensitivity, and negative tau expression may serve as a prognostic factor and a predictor of paclitaxel/platinum response [11,37]. Here, MAPT is linked to ovarian carcinoma.